MEDICAMEQ.NSE

Medicamen Biotech Ltd.

In this briefing: The Week Ahead Course Correction? Primer: IDBI Bank Ltd (IDBI IN) - Sep 2025 Primer: Punjab National Bank (PNB IN) - Sep 2025 The Beat Ideas: Shivalik Rasayan: Does USFDA Approval Marks a New Growth Chapter? The Climate Change Threat to Productivity 1. The Week Ahead Course Correction? US government shutdown likely, with significant impact on data releases US payrolls report delayed by potential government shutdown, expected to show improvement in September Nomura's chief economist for developed markets discusses potential outcome of government shutdown and expectations for US payrolls data This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. 2. Primer: IDBI Bank Ltd (IDBI IN) - Sep 2025 IDBI Bank has demonstrated a significant financial turnaround, marked by robust profit growth and a substantial reduction in non-performing assets (NPAs). This improvement has been heavily supported by capital infusions from the Government of India and Life Insurance Corporation of India (LIC).

In this briefing: Primer: IDBI Bank Ltd (IDBI IN) - Sep 2025 Primer: Punjab National Bank (PNB IN) - Sep 2025 The Beat Ideas: Shivalik Rasayan: Does USFDA Approval Marks a New Growth Chapter? The Climate Change Threat to Productivity ReNew Energy Global (RNW US): Decision Time On NBIO 1. Primer: IDBI Bank Ltd (IDBI IN) - Sep 2025 IDBI Bank has demonstrated a significant financial turnaround, marked by robust profit growth and a substantial reduction in non-performing assets (NPAs). This improvement has been heavily supported by capital infusions from the Government of India and Life Insurance Corporation of India (LIC). The impending privatization, with the government and LIC set to divest a 60.72% stake, stands as the most critical forward-looking catalyst. This strategic sale is expected to enhance operational efficiency, improve governance, and unlock value for shareholders. Despite the positive financial trajectory, the bank's stock has underperformed its peers. Concerns remain regarding the sustainability of performance post-privatization and corporate governance issues, highlighted by disproportionate increases in executive remuneration.

In this briefing: The Beat Ideas: Shivalik Rasayan: Does USFDA Approval Marks a New Growth Chapter? The Climate Change Threat to Productivity ReNew Energy Global (RNW US): Decision Time On NBIO Relative Value Opportunities in Asia-Pac, Pair Trade Roundup (29 Sep) Nelcast Ltd - Plant Visit Insights, Small-Cap Rising Star Gearing Up for Explosive Growth 1. The Beat Ideas: Shivalik Rasayan: Does USFDA Approval Marks a New Growth Chapter? Shivalik Rasayan, once focused on agrochemicals, has entered pharmaceuticals by acquiring Medicamen Biotech and securing USFDA approval for its new API plant at Dahej-II in 2024 . The company is transforming into a diversified chemicals and pharma player . Investments in R&D, larger agrochemical capacity, and regulated pharma access open pathways for higher-margin and sustainable growth. Despite past issues of underutilized plants, high costs, and delays , recent approvals and new facilities position Shivalik Rasayan for steadier performance and long-term growth if execution remains strong. 2.